1-3 of 3
Sui Shen
Close
Sort by
Journal Articles

A Preliminary Report of a Phase I Study of Zevalin® Using a Modified Treatment Regimen for Relapsed or Refractory CD20+ B-Cell Follicular or Transformed Non-Hodgkin’s Lymphoma (NHL).

Andres Forero-Torres, MD, Jatin Shah, MD, Stephen Besh, MD, Susan Knox, MD, Ivana Micallef, MD, George Wiseman, M.D, Thomas Witzig, MD, Albert Lobuglio, MD, Sui Shen, PhD, Michael Goris, MD, Jeanne Connor, Ruby Meredith, MD, PhD
Journal: Blood
Blood (2005) 106 (11): 4798.
https://doi.org/10.1182/blood.V106.11.4798.4798
Published: 2005
Journal Articles

Treatment of a B-Cell, Primary Central Nervous System Lymphoma Patient with Radioimmunotherapy Using Zevalin®: A Proof-of-Principal Case.

Ruby Meredith, MD, Louis Nabors, MD, Sui Shen, PhD, John Fiveash, MD, Sthepen Besh, MD, PhD, Albert LoBuglio, MD, Andres Forero-Torres, MD
Journal: Blood
Blood (2004) 104 (11): 4639.
https://doi.org/10.1182/blood.V104.11.4639.4639
Published: 2004
Journal Articles

Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma

Clinical Trials & Observations
Andres Forero, Paul L. Weiden, Julie M. Vose, Susan J. Knox, Albert F. LoBuglio, Jordan Hankins, Michael L. Goris, Vincent J. Picozzi, Don B. Axworthy, Hazel B. Breitz, Robert B. Sims, Richard G. Ghalie, Sui Shen, Ruby F. Meredith
Journal: Blood
Blood (2004) 104 (1): 227–236.
https://doi.org/10.1182/blood-2003-09-3284
Published: 2004